Novartis
Novartis AG, a leading global healthcare company headquartered in Switzerland (CH), has established itself as a pioneer in the pharmaceutical industry since its founding in 1996. With a strong presence in key operational regions including North America, Europe, and Asia, Novartis focuses on innovative medicines, generics, and eye care products. The company is renowned for its commitment to research and development, producing unique therapies in areas such as oncology, cardiology, and immunology. Notable achievements include the development of groundbreaking treatments that have transformed patient care. As a top player in the pharmaceutical market, Novartis continues to drive advancements in healthcare, making significant contributions to global health and well-being.
DitchCarbon Score
How does Novartis's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Novartis's reported carbon emissions
As of 2023, Novartis reported total greenhouse gas emissions of approximately 4,868,900,000 kg CO2e, with emissions distributed across various scopes: 251,100,000 kg CO2e from Scope 1, 44,100,000 kg CO2e from Scope 2, and 4,573,700,000 kg CO2e from Scope 3. The company has set ambitious climate commitments, aiming for carbon neutrality in its own operations (Scope 1 and 2) by 2025 and across its entire supply chain (Scope 1, 2, and 3) by 2030. To achieve these goals, Novartis has established a Science Based Target, committing to a 35% reduction in absolute emissions across its value chain from a 2016 baseline by 2030. Furthermore, the company has pledged to reach net zero emissions by 2040, with interim targets of a 90% reduction in Scope 1 and 2 emissions and a 42% reduction in Scope 3 emissions by 2030, also based on a 2022 baseline. These initiatives reflect Novartis's commitment to sustainability and its proactive approach to addressing climate change within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2010 | 2011 | 2012 | 2013 | 2014 | 2016 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 922,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novartis is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
